Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TIMP3 | P35625 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565078 | 0.97 | LMNA (0.56) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL518141 | 0.97 | LMNA (0.56) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL11610779 | 0.89 | TSHR (0.62) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL20421629 | 0.84 | LMNA (0.72) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL545629 | 0.84 | LMNA (0.72) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL979380 | 0.82 | LMNA (0.56) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL150334 | 0.81 | LMNA (0.77) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL14455222 | 0.80 | LMNA (0.41) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| Formaldehyde SCHEMBL28763457 | 0.78 | LMNA (0.65) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| Formaldehyde SCHEMBL27960582 | 0.78 | LMNA (0.65) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104053313-B | The method for filling through hole | 罗门哈斯电子材料有限公司 | 2017-08-08 | — | — | CN | disclosed |
| CN-104053313-A | Method Of Filling Through-holes | ROHM & HAAS ELECT MAT | 2014-09-17 | — | — | CN | disclosed |
| US-7250526-B2 | Transfer hydrogenation process and catalyst | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2007-07-31 | — | — | US | disclosed |
| EP-1339655-B1 | TRANSFER HYDROGENATION PROCESS AND CATALYST | AVECIA PHARMACEUTICALS LTD (GB) | 2007-07-25 | — | — | EP | disclosed |
| US-20040102313-A1 | Transfer hydrogenation process and catalyst | NPIL PHARMACEUTICASL (UK) LIMITED (GB) | 2004-05-27 | — | — | US | disclosed |
| EP-1339655-A1 | TRANSFER HYDROGENATION PROCESS AND CATALYST | Avecia Limited (GB) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002044111-A1 | TRANSFER HYDROGENATION PROCESS AND CATALYST | AVECIA LIMITED (GB) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102313-A1 | Transfer hydrogenation process and catalyst | HRH3, HRH4, HRH1 | LMNA 4712/4885ALDH1A1 1104/4885TSHR 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.